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Aluminum(A1) is found in parenteral nutrition (PN) solutions, accumulating in bone and liver of patients receiving PN therapy. A1 is associated with low-turnover osteomalacia in PN patients but not with liver disease. PN patients may also develop cholestasis(~S).
We studied whether A1 could produce CS in rats (160-ZOOg) given A1 intravenously(1~) 5 mg/kg/d for 14d (Group 1) (n=7) and 7d (Group 11) (n=8) and 1 mg/kg/d for 14d (Group 111) (n=6).
Each group was pair-fed with littermate controls(C) given saline IV. Serum(S) total bile acids(~A), bile flow(BF), and A1 in bile(B) and urine(U) were determined. Results: In all groups BA1 excretion was only 3-7% of UA1 excretion. Thus, A1 can produce CS in rats in both a dose and time-related manner and must be considered in the etiology of TPN-associated cholestasis. DIOS, a common cause of abdominal pain in CF patients, is due to impaction of muco-feculent material in distal ileum and cecum. Conventional therapy with mucolytics, laxatives and retention enemas is often unsatisfactory and may require hospitalization. We have extensive experience with the use of intestinal lavage with Colytelym. 22 CF patients (mean 21.8 yrs, range 13-34 yrs, 15 male) presented with abdominal pain and a mass in the right iliac fossa; 3 vomited and 13 had acute weight loss. In the first lavage 5.6t1.9 L (MtSD) of Golytelym were given p.0. (n=14) or via n-g tube (n=8) over a period of 5.6t2.4 hrs. Body weight and serum electrolytes did not change significantly. No serious side effects occurred. Minor symptoms included bloating (n=12), nausea (n=8), vomiting (n=l), increased urine output (n=7) and chills (n=3). All but one patient reported impressive relief of symptoms, and remained pain-free for an average of 3 months (range 1 -19 months). We developed a score to assess DIOS with regard to pain (absent -acute obstruction; range 0-30) and radiological signs of impaction (absent -severe; range 0-30). Lavage led to a significant reduction of pain (20.5t4.9 vs. 1.4t4.7; p <0.0001) and of radiologic score (13.5f5.6 vs. 4.3t5.4; p <0.0001). During follow up of 1-22 months, 8 patients needed a total of 26 (range 1-7) further courses of Golytelyol. 6 patients were treated at home, resulting in reduced hospitalization. In our experience intestinal lavage is a well accepted, safe and effective therapy for DIOS. (Lancet 1985; 2:527) . This study aims to determir.e the extent of A1 contamination in whole milk and infant formulas. Similar products from different manufacturers (M) and different lots (L) were measured for A1 using electrothermal atomic absorption. A1 measurements were made directly from the samples or after dilution with A1 free water. A1 content was lowest in human milk (27t.6 pgll, d S E , n=6), whole cow milk (26t2 pgll, n=3), bottled glucose water (13 and 17 pg/l, n=2), and sterile water (25f8 pg/l, n=3); highest in highly processed and modified formulas including soy formula (1102f163 ug/l n=14 from 3~1 1 2~1 , "premature" formula (660f68 pgll, n=13 from 2M/10~), special formulas with modified protein, carbohydrate or fat (983f134 pg/l, n=7 from 1 M 1 7~ and 3 products). A1 content of humanized CM formulas was 203f16 ug/l, n=31 from 3M126L and 14 products, and for bottled glucose-electrolyte solution was 73t6 pgll, n=3. There were no significant differences in A1 content of similar products from different manufacturers. Thus there are marked differences in A1 loading depending on the type of formula used. We suggest that A1 contamination of infant formulas may be lowered by altering manufacturing procedures and the use of low A1 additives. 
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John S. Latimer and Merrily Poth. (Spon. by R.E. Johnsonbaugh). USUHS, Dept. of Peds, Rethesda, MD. Free radical mechanisms have been implicated in mediating tissue damage after ischemia in several different organ systems. Vitamin E serves as a major defense against free radical injury and vitamin E deficiency may be a contributing factor in the increased vulnerability of newborn and preterm infants to ischemic injury. Therefore we set up an ischemic gut model in the rat to study the effects of vitamin E deficiency and repletion on Free radical propaRacion and on mucosal enzyme levels. Weanling Sprague-Dawley rats were placed on vitamin E deficient or replete diets for 13-15 wks and then subjected to a 45 min cranial mesenteric artery occlusion and 15 min reperfusion or timed laparotomy. Mucosal scrapings from jejunum and ileum were homogenized and assayed for in vitro lipid peroxidation using thiobarbituric acid assay of malondialdehyde. In addition, a mucosal enzyme, sucrase, was measured in jejunal homogenates. Increased lipid peroxidation was seen in vitamin E deficient small bowel and this was further increased after ischemia. Vitamin E added to the assay in vitro or given to the rats in vivo prevented this increased lipid peroxidation. A higher concentration of vitamin E was needed for inhibition of lipid peroxidation after ischemic insult. Ischemia resulted in a decrease in sucrase in jejunum of vitamin E deficient but not in vitamin E replete rats. Thus vitamin E deficiency potentiates the effect of ischemia on free radical formation, and enhances the acute functional gut damage, as measured by a decrement in mucosal enzyme activity.
